Edition:
United States

Supernus Pharmaceuticals Inc (SUPN.OQ)

SUPN.OQ on NASDAQ Stock Exchange Global Market

21.03USD
22 Jul 2016
Change (% chg)

$0.03 (+0.14%)
Prev Close
$21.00
Open
$20.96
Day's High
$21.20
Day's Low
$20.86
Volume
86,336
Avg. Vol
201,605
52-wk High
$23.15
52-wk Low
$9.52

SUPN.OQ

Chart for SUPN.OQ

About

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi... (more)

Overall

Beta: 1.73
Market Cap(Mil.): $1,039.33
Shares Outstanding(Mil.): 49.42
Dividend: --
Yield (%): --

Financials

  SUPN.OQ Industry Sector
P/E (TTM): 59.27 36.15 37.05
EPS (TTM): 0.35 -- --
ROI: 14.29 15.11 14.35
ROE: 16.24 16.17 15.56

BRIEF-Supernus Pharmaceuticals CEO Jack Khattar joins scPharmaceuticals board

* Supernus Pharmaceuticals founder and CEO Jack Khattar joins scPharmaceuticals board of directors Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Jul 12 2016

BRIEF-Supernus reiterates guidance

* Remains in discussions with FDA regarding its supplemental new drug application, or SNDA, for migraine

Jun 16 2016

BRIEF-Supernus enters partial settlement agreement with Actavis on oxtellar xr

* Supernus enters into partial settlement agreement with Actavis on oxtellar xr

May 10 2016

BRIEF-Supernus Pharmaceuticals Q1 earnings per share $0.08

* Q1 earnings per share view $0.09 -- Thomson Reuters I/B/E/S

May 03 2016

BRIEF-Supernus Pharmaceuticals CEO 2015 total compensation $3.2 mln

* CEO Jack A. Khattar's 2015 total compensation was $3.2 million versus $1.7 million in 2014 - SEC filing Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Apr 19 2016

Supernus beats Allergan over epilepsy drug patents

A federal judge on Friday said Allergan Plc's planned generic version of a drug meant to treat epilepsy infringed patents belonging to Supernus Pharmaceuticals Inc.

Feb 05 2016

Supernus beats Allergan over epilepsy drug patents

A federal judge on Friday said Allergan Plc's planned generic version of a drug meant to treat epilepsy infringed patents belonging to Supernus Pharmaceuticals Inc.

Feb 05 2016

UPDATE 1-Supernus beats Allergan over epilepsy drug patents

Feb 5 A federal judge on Friday said Allergan Plc's planned generic version of a drug meant to treat epilepsy infringed patents belonging to Supernus Pharmaceuticals Inc.

Feb 05 2016

Supernus beats Allergan over epilepsy drug patents

Feb 5 A federal judge on Friday said Allergan Plc's plan to sell a generic version of a drug meant to treat epilepsy infringed patents belonging to Supernus Pharmaceuticals Inc.

Feb 05 2016

Competitors

  Price Chg
Abbott Laboratories (ABT.N) $43.17 +0.13
AstraZeneca plc (AZN.L) 4,612.50p +89.00
Eli Lilly and Co (LLY.N) $81.59 +1.19
Shire PLC (SHP.L) 4,914.00p +19.00
Shire PLC (3159084.L) -- --
Smiths Group plc (SMIN.L) 1,153.00p +53.00

Earnings vs. Estimates